GlassScriptPhysician profile
Viktorya Belenkova
NPI 1053493197
$2,582.21
in general payments reported to CMS, 2019-2025
16 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $304 · 2021: $410 · 2022: $491 · 2023: $372 · 2024: $288 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $733.18 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Onefit Contact Lens |
| Alcon Vision LLC | $544.75 | 2019-2025 | Precision7, Precision 1, Dailies |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $267.97 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $208.35 | 2022-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $174.39 | 2022-2025 | |
| Oyster Point Pharma, INC. | $118.43 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $98.86 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $90.39 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $73.33 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $71.02 | 2022-2023 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $62.56 | 2020-2021 | |
| Allergan, INC. | $46.38 | 2021-2022 | |
| Biotissue Holdings INC. | $29.66 | 2025 | |
| Kala Pharmaceuticals, INC. | $24.44 | 2021 | |
| Shire North American Group INC | $23.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $14.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktorya Belenkova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.